Abstract

AimTo determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer.MethodsIn this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects.ResultsThe presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively.DiscussionThe inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.

Highlights

  • Breast cancer is the most commonly diagnosed cancer worldwide with a substantial public health burden as a result of approximately 2.3 million annual cases. in February 2021, the WHO announced that breast cancer has overtaken lung cancer as the world’s most frequent cancer [1, 2]

  • Figueroa et al, have documented this in an international evaluation of the impact of the pandemic on breast cancer early detection and screening on behalf of the Covid and Cancer Modelling Consortium (CCGMC) Working Group 2; demonstrating pauses in the national screening programs and stage shifting being reported in 9 countries [4]

  • We report a cohort study on immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer, who were vaccinated as a part of a national plan for vaccination of patients with special diseases

Read more

Summary

Introduction

Breast cancer is the most commonly diagnosed cancer worldwide with a substantial public health burden as a result of approximately 2.3 million annual cases. in February 2021, the WHO announced that breast cancer has overtaken lung cancer as the world’s most frequent cancer [1, 2]. The pandemic has affected the cancer population, especially those with breast cancer. There has been a delay in diagnosis and treatment, which may result in more patients with more advanced stages of disease, who will require more intensive treatment. This could result in an increase in morbidity and mortality. Figueroa et al, have documented this in an international evaluation of the impact of the pandemic on breast cancer early detection and screening on behalf of the Covid and Cancer Modelling Consortium (CCGMC) Working Group 2; demonstrating pauses in the national screening programs and stage shifting being reported in 9 countries [4]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.